Literature DB >> 3647718

The prevalent cohort study and the acquired immunodeficiency syndrome.

R Brookmeyer, M H Gail, B F Polk.   

Abstract

The acquired immunodeficiency syndrome (AIDS) is caused by a retrovirus, the human immunodeficiency virus (HIV). A rapid and convenient method to identify additional cofactors or risk modifiers and markers of disease progression is to study a cohort prevalent with HIV antibody. However, because the time of viral infection is usually unknown in the cohort, there are several potential sources of bias. Three sources of bias in a prevalent cohort study are identified assuming a proportional hazards model: onset confounding, differential length-biased sampling, and frailty selection. A number of problems in the interpretation of results on markers from a prevalent cohort also are considered. It is concluded that risk estimates derived from a prevalent cohort are not directly comparable to risk estimates derived from an incident cohort.

Entities:  

Mesh:

Year:  1987        PMID: 3647718     DOI: 10.1093/oxfordjournals.aje.a114646

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  15 in total

Review 1.  The Healthy Worker Survivor Effect: Target Parameters and Target Populations.

Authors:  Daniel M Brown; Sally Picciotto; Sadie Costello; Andreas M Neophytou; Monika A Izano; Jacqueline M Ferguson; Ellen A Eisen
Journal:  Curr Environ Health Rep       Date:  2017-09

Review 2.  Predicting the future of the AIDS epidemic and its consequences for the health care system of New York City.

Authors:  M H Alderman; E E Drucker; A Rosenfield; C Healton
Journal:  Bull N Y Acad Med       Date:  1988-03

3.  Predicting time to threshold for initiating antiretroviral treatment to evaluate cost of treatment as prevention of human immunodeficiency virus.

Authors:  Miranda L Lynch; Victor DeGruttola
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2015-02-01       Impact factor: 1.864

Review 4.  The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease. A review of the literature.

Authors:  D R Hoover
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

5.  Sample size calculations for prevalent cohort designs.

Authors:  Hao Liu; Yu Shen; Jing Ning; Jing Qin
Journal:  Stat Methods Med Res       Date:  2016-07-11       Impact factor: 3.021

6.  Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy.

Authors:  Benoît Marin; Rodolphe Thiébaut; Heiner C Bucher; Virginie Rondeau; Dominique Costagliola; Maria Dorrucci; Osamah Hamouda; Maria Prins; Sarah Walker; Kholoud Porter; Caroline Sabin; Geneviève Chêne
Journal:  AIDS       Date:  2009-08-24       Impact factor: 4.177

7.  Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals.

Authors:  Samuel O Pine; M Juliana McElrath; Pierre-Yves Bochud
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

8.  HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.

Authors:  A Cozzi Lepri; P Pezzotti; M Dorrucci; A N Phillips; G Rezza
Journal:  BMJ       Date:  1994-12-10

9.  Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centres in the United Kingdom.

Authors:  S C Darby; C R Rizza; R Doll; R J Spooner; I M Stratton; B Thakrar
Journal:  BMJ       Date:  1989-04-22

10.  A new approach to estimating AIDS incubation times: results in homosexual infected men.

Authors:  S Chevret; D Costagliola; J J Lefrere; A J Valleron
Journal:  J Epidemiol Community Health       Date:  1992-12       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.